Edition:
United Kingdom

Amicus Therapeutics Inc (FOLD.OQ)

FOLD.OQ on NASDAQ Stock Exchange Global Market

11.97USD
19 Oct 2018
Change (% chg)

$-0.32 (-2.60%)
Prev Close
$12.29
Open
$12.30
Day's High
$12.65
Day's Low
$11.93
Volume
621,082
Avg. Vol
735,304
52-wk High
$17.60
52-wk Low
$11.58

Select another date:

Mon, Aug 13 2018

Photo

Amicus sets $315,000 price for new Fabry disease treatment

Amicus Therapeutics on Monday set an average price of $315,000 per year for its newly approved Fabry disease treatment, a price it believes is below that of the main existing treatment in the United States.

UPDATE 1-Amicus sets $315,000 price for new Fabry disease treatment

Aug 13 Amicus Therapeutics on Monday set an average price of $315,000 per year for its newly approved Fabry disease treatment, a price it believes is below that of the main existing treatment in the United States.

Amicus sets $315,000 price for new Fabry disease treatment

Aug 13 Amicus Therapeutics priced its new Fabry disease treatment at an average $315,000 per year in the United States, the company said on Monday.

Amicus Therapeutics receives U.S. approval for Fabry disease drug

U.S. health regulators on Friday approved Amicus Therapeutics' Galafold, the first oral therapy to treat Fabry disease, a rare, sometimes fatal condition in which accumulation of fat damages several organs.

UPDATE 2-Amicus Therapeutics receives U.S. approval for Fabry disease drug

Aug 10 U.S. health regulators on Friday approved Amicus Therapeutics' Galafold, the first oral therapy to treat Fabry disease, a rare, sometimes fatal condition in which accumulation of fat damages several organs.

Amicus Therapeutics receives U.S. approval for Fabry disease drug

Aug 10 U.S. health regulators on Friday approved Amicus Therapeutics' Galafold, the first oral therapy to treat Fabry disease, a rare, sometimes fatal condition in which accumulation of fat damages several organs.

BRIEF-Amicus Therapeutics Reports Q1 Loss Per Share Of $0.28

* AMICUS THERAPEUTICS ANNOUNCES FIRST QUARTER 2018 FINANCIAL RESULTS AND CORPORATE UPDATES

Select another date: